A detailed history of Ubs Group Ag transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 401,159 shares of EYPT stock, worth $2.89 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
401,159
Previous 189,903 111.24%
Holding current value
$2.89 Million
Previous $1.65 Million 94.01%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.58 - $10.54 $1.6 Million - $2.23 Million
211,256 Added 111.24%
401,159 $3.21 Million
Q2 2024

Aug 13, 2024

SELL
$8.16 - $22.89 $2.18 Million - $6.11 Million
-266,723 Reduced 58.41%
189,903 $1.65 Million
Q1 2024

May 13, 2024

SELL
$19.93 - $29.71 $2.34 Million - $3.49 Million
-117,543 Reduced 20.47%
456,626 $9.44 Million
Q4 2023

Feb 09, 2024

BUY
$5.71 - $24.13 $270,202 - $1.14 Million
47,321 Added 8.98%
574,169 $13.3 Million
Q3 2023

Nov 09, 2023

BUY
$7.99 - $15.36 $3.49 Million - $6.72 Million
437,190 Added 487.62%
526,848 $4.21 Million
Q2 2023

Aug 11, 2023

BUY
$3.03 - $9.0 $269,542 - $800,622
88,958 Added 12708.29%
89,658 $780,000
Q4 2022

Feb 08, 2023

BUY
$2.37 - $7.2 $237 - $720
100 Added 16.67%
700 $2,000
Q2 2022

Aug 10, 2022

SELL
$7.25 - $12.71 $6,699 - $11,744
-924 Reduced 60.63%
600 $5,000
Q1 2022

May 16, 2022

SELL
$8.67 - $14.11 $267,278 - $434,983
-30,828 Reduced 95.29%
1,524 $18,000
Q4 2021

Feb 14, 2022

BUY
$10.18 - $18.4 $319,000 - $576,582
31,336 Added 3084.25%
32,352 $396,000
Q3 2021

Nov 15, 2021

SELL
$7.51 - $11.72 $5,482 - $8,555
-730 Reduced 41.81%
1,016 $10,000
Q2 2021

Aug 13, 2021

BUY
$8.69 - $11.08 $10,819 - $13,794
1,245 Added 248.5%
1,746 $16,000
Q1 2021

May 12, 2021

BUY
$8.89 - $14.92 $8 - $14
1 Added 0.2%
501 $5,000
Q4 2020

Feb 11, 2021

BUY
$3.7 - $6.58 $1,850 - $3,290
500 New
500 $3,000

Others Institutions Holding EYPT

About EyePoint Pharmaceuticals, Inc.


  • Ticker EYPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,072,200
  • Market Cap $245M
  • Description
  • EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...
More about EYPT
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.